Literature DB >> 32605862

Increased levels of cytokines in the aqueous humor correlate with the severity of diabetic retinopathy.

Shuang Song1, Xiaobing Yu2, Peng Zhang1, Hong Dai1.   

Abstract

AIMS: To determine the associations between the levels of certain cytokines in the aqueous humor and the severity of diabetic retinopathy.
METHODS: A total of 103 patients (one eye per patient) who received intravitreal injection with ranibizumab for diabetic retinopathy were enrolled and divided into 3 groups: nonproliferative diabetic retinopathy (NPDR) with macular edema group (42 eyes), proliferative diabetic retinopathy (PDR) group (40 eyes) and neovascular glaucoma due to PDR (NVG-PDR) group (21 eyes). The concentrations of interleukin (IL)-6, IL-8, IL-10, vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and monocyte chemoattractant protein-1 (MCP-1) in the aqueous humor were measured.
RESULTS: In this study, 42, 40 and 21 patients (one eye per patient) were included in the NPDR, PDR and NVG-PDR groups, respectively. The median concentrations of IL-6, IL-8, IL-10, VEGF, TGF-β, VCAM-1, ICAM-1 and MCP-1 in the groups were measured. The levels of these 8 cytokines increased with the severity of diabetic retinopathy, especially in the NVG-PDR group. Compared with those in the NPDR group, the aqueous concentrations of these 8 cytokines were higher in the PDR group and were the highest in the NVG-PDR group. There were significant differences in all cytokines among the three groups (P < 0.05). Multivariate analysis showed that in the NPDR and PDR groups, the risk of PDR associated with elevated levels of TGF-β (P = 0.0004, OR 1.11, 95% CI [1.05-1.18]) and ICAM-1 (P = 0.0408, OR 10.75, 95% CI [1.10-104.61]). In the PDR and NVG groups, the risk of NVG associated with elevated levels of IL-10 (P = 0.0486, OR 0.7040, 95% CI [0.4966, 0.9979]), VEGF (P = 0.0279, OR 0.9963, 95% CI [0.9931, 0.9996]), and VCAM-1 (P = 0.0316, OR 0.9998, 95% CI [0.9996, 0.99998]). In the three groups, the risk of developing NVG associated with elevated levels of TGF-β (P < 0.001, OR 1.04, 95% CI [1.02, 1.05]).
CONCLUSIONS: The levels of these eight cytokines in the aqueous humor increased with the severity of diabetic retinopathy, especially in NVG-PDR. This study suggests that TGF-β, ICAM-1, IL-10, VEGF, and VCAM-1 may play a role in the progression of diabetic retinopathy, especially TGF-β, which may plays a significant role in NVG-PDR. These cytokines potentially may be used as biomarkers to predict the progress of diabetic retinopathy, contribute to the choice of treatment options and/or monitor treatment responses.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aqueous humor; Cytokines; Diabetic retinopathy; Neovascular glaucoma

Year:  2020        PMID: 32605862     DOI: 10.1016/j.jdiacomp.2020.107641

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  13 in total

Review 1.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

2.  Effect of intravitreal ranibizumab on fibrovascular membranes in patients with proliferative diabetic retinopathy.

Authors:  Ze-Yu Liang; Yi-Peng Wang; Jing Li; Wen-Chao Yang; Yong-Fang Tu; Yue Zhang; Song Chen
Journal:  Int J Ophthalmol       Date:  2022-10-18       Impact factor: 1.645

3.  Downregulation of angiogenic factors in aqueous humor associated with less intraoperative bleeding in PDR patients with NVG receiving conbercept: a randomized controlled trial.

Authors:  Qing Xu; Chaoju Gong; Lei Qiao; Ruifang Feng; Haiyang Liu; Yalu Liu; Liu Yang; Wei Fan; Lina Guan; Jie Li; Yipeng Zhang; Suyan Li
Journal:  BMC Ophthalmol       Date:  2022-05-18       Impact factor: 2.086

4.  Pars plana vitrectomy assisted by intravitreal injection of conbercept enhances the therapeutic effect and quality of life in patients with severe proliferative diabetic retinopathy.

Authors:  Qin Wang; Hui Cai; Dahua Xu; Lin Cui; Yan Zhang; Mei Chen
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

5.  Systemic and vitreous biomarkers - new insights in diabetic retinopathy.

Authors:  Bernardete Pessoa; João Heitor; Constança Coelho; Magdalena Leander; Pedro Menéres; João Figueira; Angelina Meireles; Melo Beirão
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-24       Impact factor: 3.535

Review 6.  Retinal Vascular Endothelial Cell Dysfunction and Neuroretinal Degeneration in Diabetic Patients.

Authors:  Malgorzata Mrugacz; Anna Bryl; Katarzyna Zorena
Journal:  J Clin Med       Date:  2021-01-25       Impact factor: 4.241

Review 7.  Retinal Neurodegeneration in Diabetes: an Emerging Concept in Diabetic Retinopathy.

Authors:  Mira M Sachdeva
Journal:  Curr Diab Rep       Date:  2021-12-13       Impact factor: 4.810

8.  Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells.

Authors:  Ying Tian; Fan Zhang; Yefeng Qiu; Shuang Wang; Feng Li; Jiawei Zhao; Chao Pan; Yong Tao; Di Yu; Wei Wei
Journal:  Nat Biomed Eng       Date:  2021-07-26       Impact factor: 25.671

9.  Association between Inflammatory Factors in the Aqueous Humor and Hyperreflective Foci in Patients with Intractable Macular Edema Treated with Antivascular Endothelial Growth Factor.

Authors:  Min Li; Jing Li; Kaichuan Chen; Jia Wang; Minjie Sheng; Bing Li
Journal:  Dis Markers       Date:  2021-06-07       Impact factor: 3.434

Review 10.  Intraocular fluid biomarkers (liquid biopsy) in human diabetic retinopathy.

Authors:  Edoardo Midena; Luisa Frizziero; Giulia Midena; Elisabetta Pilotto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-07-03       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.